The Latest Breaking News from FDA

KANSAS CITY, Mo. — For the first time since 2015, Missouri has returned to executing multiple people on death row per year — two in 2022 and two scheduled so far for 2023 — but details about the process remain shrouded in secrecy.

ATLANTA -- Ira Katz bustles at his pharmacy in Atlanta's Little Five Points neighborhood this cough season, serving patients who need medicine for respiratory viruses like COVID-19. He dispenses occasional packages of Paxlovid, a drug designed to nip COVID in the bud. But there aren’t as many of those Paxlovid…

WASHINGTON — A joint investigation released Thursday by House Democrats identified unusual collaboration between Food and Drug Administration officials and drugmaker Biogen, highlighting potential problems in the agency’s approval of the controversial Alzheimer’s drug Aduhelm.

The Evie smart ring targets women's health and is aiming to be FDA-approved. Movano says it will ideally cost less than $300 when it launches sometime in 2023.

Instead of a Santa Claus rally, the market continues to experience volatility at the end of the year with uncertainties surrounding the reopening of the Chinese economy and a looming recession due to seemingly unending interest rate hikes. Given this backdrop, loading up on fundamentally strong stocks Walmart (WMT), Pfizer…

House Democrats releases a report highlighting potential problems in the FDA's approval of Alzheimer's drug Aduhelm.

Alydia Health's Jada system for postpartum hemorrhage took 11 years to reach the market; being a women's health product made its road tougher.

With recent economic data showing promise, the chances of a soft landing for the economy are increasing. Hence, it could be wise to invest in fundamentally sound stocks CVS Health (CVS), Ooma (OOMA), and Neurocrine Biosciences (NBIX), which possess solid growth attributes. Read on….

This is the second time a company has recalled blood-pressure medication in recent months.